CNBC
06 Aug 2026, 13:45 UTC · 1h ago
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
06 Aug 2026, 13:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
6 claims · each scored for market impact
Eli Lilly's revenue grew 48% year-over-year, and the company raised its full-year revenue guidance. — Strong organic growth and raised guidance signal a dominant market position and high confidence in near-term cash flow.
+0.80Eli Lilly held a 60.9% share of the U.S. obesity and diabetes drug market in Q2, significantly leading Novo Nordisk's 38.8%. — Market share dominance suggests a competitive advantage that allows Lilly to capture the majority of the sector's growth.
+0.60Novo Nordisk's experimental drug CagriSema failed to match the blood sugar control efficacy of Eli Lilly's Zepbound in a large trial. — Failure to match the gold-standard competitor undermines Novo's long-term pipeline and its ability to regain market share.
-0.60Continue reading
6 related stories
Top 1 mover · tap to explore
Novo Nordisk's late-stage heart drug, ziltivekimab, failed to reduce major cardiovascular events compared to a placebo. — This failure limits Novo's ability to diversify its portfolio away from its reliance on obesity and diabetes drugs.
-0.50Which stocks this story touches
The company reported blistering growth, beat estimates, raised guidance, and is viewed as the market's momentum story.
Despite beating estimates, the company faced share price declines due to pipeline concerns, mixed trial results for CagriSema, and a failed heart drug trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
25m ago
